Login to Your Account



ThromboGenics, Alcon Get European Nod for Jetrea

By Cormac Sheridan
Staff Writer

Friday, January 18, 2013
europe_resized.jpg

ThromboGenics NV and its partner, the Alcon unit of Novartis AG, received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Jetrea (ocriplasmin) as a treatment for vitreous macular traction, paving the way for a European launch in the second quarter.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription